Delhi based Vyome Biosciences, a dermatology company focused on developing novel and innovative treatments for common skin conditions such as dandruff, acne, pigmentation disorders and wound healing, has closed Series A financing round of Rs. 18.50 crore. The round was led by IndoUS Venture Partners (IUVP), with Aarin Capital and Navam Capital as co- investors.
Vyome will deploy the new financing to advance the clinical development of its lead anti- dandruff products, and to accelerate the pre-clinical development of its anti-acne products.
These safer and more effective next-generation treatments are being developed by harnessing emerging genetic information on the disease-causing microbes with advances in nanotechnology. Vyome has already filed multiple Indian and Global patents on these technologies.
“Our vision is to emerge as a company that launches global products from India and competes with the best in the world” said Dr Shiladitya Sengupta, Co-Founder of Vyome and Assistant Professor of Medicine at Harvard Medical School.
“Vyome is developing creative approaches that will transform how skin diseases will be treated in the future. Dermatology is one area that has not seen much innovation for over five decades but with the recent advances in science, significantly more effective solutions become possible. Vyome has attracted top talent globally, and the ability to generate multiple highly differentiated products by harnessing cutting-edge scientific platforms creates a very compelling value proposition” said Dr R.A. Mashelkar, Chairman of Vyome’s Board of Directors and former Director General of CSIR